Viridian Reports Positive Phase 1 Data for VRDN-008

The antibody-suppressing therapy showed sustained IgG reduction in healthy volunteers, with a registrational trial planned for mid-2027.

Updated on Nov. 9, 2026 in Biotech

Viridian Reports Positive Phase 1 Data for VRDN-008

Viridian Therapeutics reported positive Phase 1 results for VRDN-008, an antibody-suppression candidate that sustained IgG reduction through eight weeks in healthy volunteers. Shares of the company rose 4.69% to $29.83 on Monday following the announcement.

Why it matters

The results support the company's plan to advance VRDN-008 rapidly into pivotal development, with a registrational trial in myasthenia gravis targeted for mid-2027. The longer dosing interval and extended antibody suppression could matter for patients with autoantibody-driven conditions.

The Phase 1 study in healthy volunteers recorded a 15 to 18 day half-life for VRDN-008, up to six times longer than first-generation Fc fragments, and a 74% peak IgG reduction. Whether these pharmacokinetic and pharmacodynamic results translate to clinical benefit in patients remains unestablished.

The players

Viridian Therapeutics

Viridian Therapeutics is a biopharmaceutical company developing antibody-targeting therapies for autoimmune and related conditions.

The details

Two subcutaneous doses were given to healthy volunteers, at trial initiation and at week four. VRDN-008 pairs an Fc fragment with an albumin-binding domain to prolong antibody suppression, and no serious adverse events were reported.

Timeline

  1. January 2023: Viridian secured exclusive global rights to the enFuse platform.

  2. Week four: second VRDN-008 dose administered in the Phase 1 study.

  3. Monday: Viridian shares rose following the trial results announcement.

  4. Mid-2027: planned initiation of a registrational trial in myasthenia gravis.

Big Picture

VRDN-008 builds on Fc-fragment engineering, extending the half-life of antibody-suppressing therapies beyond first-generation designs. The albumin-binding addition positions the candidate as a longer-acting alternative in the field's effort to reduce dosing frequency.

If VRDN-008 advances, patients with antibody-mediated conditions could face less frequent injections because suppression lasts weeks rather than days. Access and timing for any approved use will depend on the outcome of the planned pivotal trials.

The takeaway

Longer-acting antibody suppression could reduce treatment burden for patients, but healthy-volunteer data are an early step that pivotal trials must confirm.

What happens next

Viridian plans to initiate at least one registrational trial of VRDN-008 in myasthenia gravis in mid-2027.

Further reading

Explore more Biotech developments shaping antibody therapies worldwide.